What is Zoonotic Disease Treatment Market Scope?
A zoonotic disease is any disease or infection that is transmissible from vertebrate animals to humans. Nearly two-thirds of human infectious diseases arise from pathogens shared with wild or domestic animals. Recently emerged zoonotic diseases include Coronaviruses, Ebola, and Influenza, among others. These diseases are transmitted via direct contact, indirect contact, or vector-borne. This possess risks to all countries; as global trade and travel expand, zoonoses are increasingly posing health concerns for the global medical community. Multisectoral collaboration, including clinicians, public health scientists, ecologists, and disease ecologists, veterinarians, economists, and others is necessary for effective management of the causes and prevention of zoonotic diseases.
The Zoonotic Disease Treatment market study is being classified and major geographies with country level break-up.
Glaxo SmithKline (United Kingdom), Novartis AG (Switzerland), Johnson & Johnson (United States), Pfizer, Inc. (United States), Sanofi S.A. (France), BioCryst Pharmaceuticals, Inc. (United States), AstraZeneca (United Kingdom), Cadila Healthcare Ltd. (India), Kedrion Biopharma Inc. (United States) and Merck & Co., Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are VBI Vaccines Inc. (United States) and Bavarian Nordic (Denmark).
Analyst at AMA have segmented the market study of Global Zoonotic Disease Treatment market by Type, Application and Region.
On the basis of geography, the market of Zoonotic Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In April 2019, La Jolla Pharmaceutical Company received the U.S FDA Breakthrough Therapy designation for LJPC-0118, an investigational drug for the treatment of severe malaria. This designation is a key regulatory milestone for the company and it will help the company to work closely with the U.S FDA for the further development of the drug.
The World Organization for Health recognizes as the most common zoonotic disease as: Lyme disease and Rocky Mountain spotted fever, Salmonella, Dengue
- The rise of emerging diseases owing to the increase in population, the growth of cities, the destruction of natural habitats, the modernization of agricultural practices, and climate change.
- Ongoing Clinical Trial Conducted By Many Pharmaceuticals Industries
- High Demand of Disease-Specific Novel Treatment
- Culture-Independent Methods in the Zoonotic Diagnostics
- Next-Generation Sequencing (NGS) Techniques to Get a Complete Understanding of the Viral Composition in Humans and Animals
- Increase in Drug Resistance in Pathogens Due To Overuse and Misuse of Antibiotics
- Low Healthcare Budget in Some Developing Countries
- Precaution during Treatment of Zoonotic Diseases to Prevent Human Infection
- Diagnosis of Zoonotic Agents, and the Description and Distribution of New Zoonotic Microorganisms and Viruses
Key Target Audience
Zoonotic Disease Vaccine Manufacturers, Raw Material Suppliers, Traders/Importers/Exporters, Government & Research Organisation, End-Use Industry and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.